3247 related articles for article (PubMed ID: 19091352)
1. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
2. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
3. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive assessment of prostatic obstruction in elderly men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
van Venrooij GE; Eckhardt MD; Boon TA
Urology; 2004 Mar; 63(3):476-80. PubMed ID: 15028441
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
6. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
[TBL] [Abstract][Full Text] [Related]
7. Incidence rates and risk factors for acute urinary retention: the health professionals followup study.
Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
J Urol; 1999 Aug; 162(2):376-82. PubMed ID: 10411042
[TBL] [Abstract][Full Text] [Related]
8. Urodynamic evaluation in diabetic patients with prostate enlargement and lower urinary tract symptoms.
Dib PT; Trigo-Rocha F; Gomes CM; Srougi M
Urol Int; 2008; 80(4):378-82. PubMed ID: 18587248
[TBL] [Abstract][Full Text] [Related]
9. Simple case definition of clinical benign prostatic hyperplasia, based on International Prostate Symptom Score, predicts general practitioner consultation rates.
Kok ET; Bohnen AM; Jonkheijm R; Gouweloos J; Groeneveld FP; Thomas S; Bosch JL
Urology; 2006 Oct; 68(4):784-9. PubMed ID: 17070353
[TBL] [Abstract][Full Text] [Related]
10. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
Parsons JK
J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
[TBL] [Abstract][Full Text] [Related]
11. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
Rosario DJ; Phillips JT; Chapple CR
J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
[TBL] [Abstract][Full Text] [Related]
12. Changes in disease specific and generic quality of life related to changes in lower urinary tract symptoms: the Krimpen study.
Kok ET; Bohnen AM; Groeneveld FP; Busschbach JJ; Blanker MH; Bosch JL
J Urol; 2005 Sep; 174(3):1055-8. PubMed ID: 16094057
[TBL] [Abstract][Full Text] [Related]
13. Clinical diagnosis of bladder outlet obstruction in men with lower urinary tract symptoms: reliability of commonly measured parameters and the role of idiopathic detrusor overactivity.
Vesely S; Knutson T; Fall M; Damber JE; Dahlstrand C
Neurourol Urodyn; 2003; 22(4):301-5. PubMed ID: 12808704
[TBL] [Abstract][Full Text] [Related]
14. High power diode laser vaporization of the prostate: preliminary results for benign prostatic hyperplasia.
Erol A; Cam K; Tekin A; Memik O; Coban S; Ozer Y
J Urol; 2009 Sep; 182(3):1078-82. PubMed ID: 19616811
[TBL] [Abstract][Full Text] [Related]
15. Impact of lower urinary tract symptoms on quality of life using Functional Assessment Cancer Therapy scale.
Batista-Miranda JE; Molinuevo B; Pardo Y
Urology; 2007 Feb; 69(2):285-8. PubMed ID: 17320665
[TBL] [Abstract][Full Text] [Related]
16. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status.
Jacobsen SJ; Jacobson DJ; Girman CJ; Roberts RO; Rhodes T; Guess HA; Lieber MM
J Urol; 1999 Oct; 162(4):1301-6. PubMed ID: 10492184
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
[TBL] [Abstract][Full Text] [Related]
18. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia].
Shao Q; Song J; Guo YW; Lu WC; Du LD
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):505-7. PubMed ID: 16078666
[TBL] [Abstract][Full Text] [Related]
20. Association among the symptoms, quality of life and urodynamic parameters in patients with improved lower urinary tract symptoms following a transurethral resection of the prostate.
Seki N; Yunoki T; Tomoda T; Takei M; Yamaguchi A; Naito S
Neurourol Urodyn; 2008; 27(3):222-5. PubMed ID: 17580358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
